About UCB, Inc.
At UCB, everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” We have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe diseases. We do that by connecting with patients and their families around the world living with the physical and social burdens of severe disease. Those connections offer new perspectives, drive innovation, and offer the hope of a new generation of therapies that are helping to transform lives.
With a team of approximately 7,500 employees and operations in more than 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research to meet unmet patient needs. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia. Additional U.S. UCB sites include global clinical development at our Research Triangle Park, North Carolina campus (UCB Biosciences, Inc.), and research supporting UCB’s pipeline in Cambridge, Massachusetts (UCB Research, Inc.).
244 articles with UCB, Inc.
Phase 3 data on VIMPAT® (lacosamide) CV in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry
- Study met primary and secondary endpoints of significantly lowering the risk of developing a second primary generalized tonic-clonic seizure (PGTCS) during a 24-week treatment and a significantly higher rate of freedom from PGTCS during the treatment period compared with placebo - Lacosamide was generally tolerated by patients enrolled in the study - Regulatory reviews, based, in part, on these data, are currently underway in the U.S., EU, Japan, and Australia
UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease
UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment
The drug is an investigational monoclonal antibody being developed for tauopathies like progressive supranuclear palsy (PSP) and Alzheimer’s disease.
UCB's resilient product portfolio drives continued company growth
The Phase 3b BE RADIANT study met its primary endpoint and all ranked secondary endpoints
New Capture the Fracture® Partnership Aims for 25% Reduction in the Incidence of Hip and Vertebral Fractures Due to Osteoporosis by 2025
International Osteoporosis Foundation Announces First-of-its-kind Partnership With University of Oxford, Amgen and UCB to Combat Global Public Health Burden of Osteoporosis
UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
Underlines UCB's leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure
1/10/2020The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups
12/9/2019It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting
14 scientific presentations will cover UCB's pipeline assets, epilepsy-specific research, and licensed medicines, including NAYZILAM, now available for the acute treatment of seizure clusters in epilepsy patients 12 years of age and older
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Amgen and UCB announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending Marketing Authorization for EVENITY® for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke.
With 16 weeks of treatment, bimekizumab-treated patients saw a 90% improvement based on clinical assessment scales.
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
UCB and Ra Pharmaceuticals Inc. announced their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma.
UCB indicates the deal is part of its strategic growth plan, dubbed the “Accelerate and Expand” phase since 2019.
Samsung BioLogics and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy, pending regulatory approvals.
UCB Half Year Report 2019: UCB's Strong Performance Enables Continued Investment Into Future Growth Drivers
The strong financial performance in the first six months 2019 enables us as planned to accelerate our investments into future growth drivers
UCB's Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients
UCB announced new Phase 2b data on the company's key pipeline molecule, bimekizumab, that showed improvements in a range of important health-related domains and general well-being for patients with active ankylosing spondylitis.ii Results from this study, which evaluated multiple treatment doses, were shared for the first time today at the Annual European Congress of Rheumatology, in Madrid.
UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.
UCB announced that the U.S. Food and Drug Administration has approved a New Drug Application for the company's newest anti-epileptic drug NAYZILAM® nasal spray CIV, a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.